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Abstract We identified a novel heterodimeric protein, lipophilin
AC, in human tears. One of its components, lipophilin A (69
residues; mass, 7575.1; pI, 9.47) was homologous to the C1 and
C2 components of prostatein (‘estramustine-binding protein’), the
major secreted protein of rat prostate. Human lipophilin C (77
residues; mass, 8854.1; pI, 4.94) was homologous to the rat
prostatein C3 component and to human mammaglobin, a protein
overexpressed in some mammary carcinomas. Tear lipophilins A
and C expand the roster of human uteroglobin superfamily
members and provide models for exploring these typically
steroid-regulated and steroid-binding molecules.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Tears play an important role in protecting, nourishing and
lubricating the cornea and external eye. Normal tears contain
approximately 10 mg/ml of protein, of which 35^45% is com-
prised of lysozyme, lactoferrin, lipocalin (‘tear-speci¢c preal-
bumin’) and IgA [1]. Perhaps because poets have displayed
more interest in tears than biochemists, the other proteins of
tears have received relatively little attention. While performing
preliminary investigations related to antimicrobial compo-
nents in tears, we noticed a distinctive molecule that had
not previously been described. We puri¢ed and sequenced
this molecule, ‘lipophilin’, and found it belonged to the utero-
globin superfamily. This report describes our studies.
2. Materials and methods
2.1. Tear collection
Under an approved protocol, healthy adult volunteers were brie£y
exposed to the vapors of freshly minced onions. Over the next 5^10
min, 100^250 Wl of stimulated tears was collected and stored at 320‡C
until used.
2.2. Puri¢cation of lipophilin heterodimers
Tears from di¡erent donors were pooled and subjected to RP-
HPLC on a 10U250 mm, Vydac 218TP510 C-18 column (Vydac,
the Separations Group, Hesperia, CA), using a linear gradient of
acetonitrile (ACN) in 0.1% tri£uoroacetic acid (TFA), that increased
in ACN concentration by 1% min31. Fractions containing lipophilin
heterodimers were identi¢ed by performing 16.5% acrylamide SDS-
PAGE gels with and without sample reduction by dithiothreitol
(DTT). Appropriate fractions were further puri¢ed by RP-HPLC on
a 4.6U250 mm Vydac 218TP54 C-18 column, using various linear
gradients of acetonitrile in 0.1% TFA or in 0.13% hepta£uorobutyric
acid (HFBA).
2.3. Other methods
Protein was measured by a micro-bicinchoninic acid (BCA) assay
(Pierce Chemicals, Rockford, IL), using bovine serum albumin stand-
ards. Quantitative amino acid analysis was performed by the PicoTag
method. Electrospray mass spectrometry was performed at UCLA in
the laboratory of Kym Faull.
2.4. Reduction of lipophilin dimers
HPLC-puri¢ed lipophilin (50 Wl, 1 mg ml31) was resuspended in a
bu¡er containing 6 M guanidine.HCl, 20 mM EDTA and 0.5 M Tris,
pH 8.07. After the solution had been £ushed with nitrogen and in-
cubated in a 52‡C water bath for 10 min, freshly prepared DTT was
added in approximately 2000-fold molar excess, relative to lipophilin.
The samples were again £ushed with nitrogen, sealed and incubated
for 2.5 h at 52‡C. Then, additional DTT was added, followed in 45
min by the addition of glacial acetic acid (5% ¢nal concentration) to
stabilize the reduced products. These were resolved by performing
RP-HPLC on a 4.6U250 mm C-18 column, with a linear ACN gra-
dient in 0.1% TFA.
2.5. Carboxamidomethylation
Rapid reduction of lipophilin heterodimers was achieved by adding
a 2000-fold molar excess of DTT at 52‡C under the anaerobic con-
ditions described above. After 2.5 h, the mixture was cooled to room
temperature, and protected from light. Iodoacetamide was added in a
3-fold molar excess, relative to DTT. After 10 min, DTT (equal in
amount to the ¢rst addition) was added to quench unreacted iodo-
acetamide. The carboxamidomethylated (CAM) derivatives of lipo-
philins A and C were then separated and puri¢ed by RP-HPLC.
2.6. Amino acid sequencing
N-terminal sequencing was performed with a Porton Model 2090E
sequencer (Beckman Instruments, Fullerton, CA), either directly, or
after transferring the CAM-modi¢ed peptide to a polyvinylidene £uo-
ride (PVDF) membrane (Millipore, Bedford, MA).
2.7. Cyanogen bromide cleavage
CAM-modi¢ed components A or C were dissolved at 0.5 mg ml31
in 0.1 N HCl and cyanogen bromide was added in slight excess, by
mass, to peptide. The mixture was incubated with occasional shaking
for 30 h at room temperature, before performing RP-HPLC to obtain
peptide fragments for mass determinations or sequencing.
2.8. Glycosylation
Lipophilin heterodimer and puri¢ed components A and C were
tested for glycosylation with the ECL glycoprotein detection kit
(Amersham, Arlington Heights, IL), using lactoferrin standards. Nei-
ther lipophilin component was glycosylated.
2.9. Western and dot blots
A conventional alkaline phosphatase detection system was used in
both blotting procedures. Reagents included a⁄nity-puri¢ed goat
anti-rabbit IgG conjugated to alkaline phosphatase (BioRad, Her-
cules, CA), 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tet-
FEBS 20614 7-8-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 8 5 2 - 7
*Corresponding author. UCLA Department of Medicine, Room CHS
37-062, 10833 LeConte Avenue, Los Angeles, CA 90095-1690, USA.
Fax: +1 (310) 206-8766. E-mail: rlehrer@med1.medsch.ucla.edu
FEBS 20614 FEBS Letters 432 (1998) 163^167
razolium (Sigma). Dot blots were done on nitrocellulose membranes
(MSI, Westboro, MA). Western blots were performed after SDS-
PAGE and electro-transfer to Immobilon-P PVDF membranes (Milli-
pore).
2.10. Polyclonal antibodies
Rabbits were immunized with synthetic peptides corresponding to
de¢ned regions of lipophilins A and C (at Research Genetics, Inc.,
Huntsville, AL). One of these peptides, KFKAPLEAVAAKMEVKK,
was identical to residues 27^43 in lipophilin A. Another, KLLEDM-
VEKTINSDIS, corresponded to residues 5^20 of lipophilin C.
When anti-lipophilin A (1:10 000 dilution) or anti-lipophilin C
(1:5000 dilution) antibody was tested in dot blots, each easily recog-
nized 6 100 picogram of the cognate lipophilin component, while
requiring about 1000-fold more (s 62 nanogram) of the noncognate
component. The smallest amounts of lipophilin AC heterodimer de-
tected in dot blots with these dilutions of anti-lipophilin A and anti-
lipophilin C were 4^8 ng and 1^2 ng, respectively. However, their
sensitivity in detecting heterodimers in both dot blots and Western
blots was improved substantially by pre-treating the membranes with
DTT (data not shown).
3. Results
3.1. Preliminary experiments
Before undertaking this investigation, we had transferred
several tear peptides to PVDF membranes and obtained their
N-terminal sequences. One of these peptides had a complex
sequence, since most of the initial sequencing 25 cycles yielded
two residues, whereas cycles 26^42 yielded a single sequence
(AKFKAPLXAVAAKMEVK). We constructed a composite
query sequence that contained the more abundant residue in
each of the ¢rst 25 cycles, followed by the unique sequence
shown above and performed a BLAST search. This query
sequence lacked any human homologue, but was identical in
15/40 (37.5%) residues to the C1 component of rat prostatein,
a known heterodimeric protein. Since its double sequence sug-
gested that the unknown human tear peptide was also hetero-
dimeric, we undertook the additional studies described below.
3.2. Demonstration in tears
When we reduced whole tears with dithiothreitol and ran
the samples on SDS-PAGE gels, a prominent band with an
apparent mass of W6 kDa was evident (Fig. 1). This band
was absent if the samples were run under nonreducing con-
ditions. This simple procedure ^ performing SDS-PAGE with
and without DTT reduction ^ provided us with a facile meth-
od of identifying the lipophilin heterodimer. Treatment of
tears with DTT also caused other changes in the electropho-
retic pattern that are evident in Fig. 1. The most prominent of
these was the disappearance of an abundant W35 kDa species
and the increased prominence of a protein with about half
that mass. We were later able to perform Western blots of
tears with antibodies to lipophilin component A (Fig. 2) and
component C (data not shown). These studies indicated that
almost all of the lipophilin peptides in nonreduced tears had a
mass ofW14 kDa, and that only small amounts of any higher
molecular weight forms were present. Consequently, the W35
kDa component of tears that was so a¡ected by DTT treat-
ment was not lipophilin.
3.3. Puri¢cation of lipophilin
We applied 1 ml aliquots of whole tears to a large C-18
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Fig. 1. SDS-PAGE analysis. The lane contents were as follows: M,
molecular weight markers, whose sizes are indicated; 1, stimulated
tears, 20 Wl ; 2, DTT-treated stimulated tears, 20 Wl ; 3, puri¢ed lipo-
philin AC heterodimer, 1 Wg; 4, puri¢ed lipophilin A monomer,
1 Wg; 5, puri¢ed lipophilin C monomer, 1 Wg. At the bottom of the
¢gure, a + sign indicates dithiothreitol (DTT)-treated samples and
a denotes samples that were not DTT-treated. The gel was stained
with Coomassie blue.
Fig. 3. RP-HPLC fractionation of whole tears on a 10U250 mm C-
18 column. Lipophilin was present in the peak indicated by the ar-
row.
Fig. 2. Western blot. Lanes 1^4 each contained 6 Wl of pooled nor-
mal tears. The samples in lanes 1 and 3 were reduced with dithio-
threitol (+), samples in lanes 2 and 4 were unreduced (0). The lanes
marked M contained molecular weight standards, as indicated. Sam-
ples 3 and 4 had been lyophilized prior to loading; samples 1 and 2
were nonlyophilized. The polyclonal rabbit antibody was raised
against a synthetic peptide corresponding to residues 27^43 of lipo-
philin A. A similar result was obtained with antibody to lipophilin
component C (not shown).
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column that was eluted with a gradient of ACN in 0.1% TFA,
and identi¢ed the lipophilin peak by performing SDS-
PAGE þ DTT reduction. Fig. 3 shows the late emerging
peak that contained the lipophilin heterodimers. These dimers
were further puri¢ed to apparent homogeneity on a small C-
18 column, using HFBA as the ion-pairing agent. The mass of
these puri¢ed lipophilin dimers was 16 424.01 þ 1.17 by ESI-
MS (data not shown). Since we recovered approximately 414
Wg of highly puri¢ed lipophilin dimer from 9 ml of pooled
human tears, its concentration in tears necessarily exceeds 45
Wg/ml.
3.4. Separation of the lipophilin monomers
When lipophilin heterodimers were reduced prior to RP-
HPLC, their monomeric components eluted separately. Com-
ponent A emerged before component C (Fig. 4) and showed
slightly less absorbance than component C at 230 nm, and
considerably less absorbance at 280 nm. This suggested that
component A was slightly smaller and contained fewer tryp-
tophan and/or tyrosine residues than component C.
3.5. Mass measurements
The masses of the reduced and CAM-modi¢ed lipophilin A
were 7574.69 and 7745.36, respectively. Since alkylating a sin-
gle half-cystine residue with iodoacetamide increases its mass
by 57 AMU, the mass di¡erence (170.67 AMU) between re-
duced and CAM-modi¢ed component A revealed that it con-
tained three half-cystine residues. We studied component C in
a similar manner and found the masses of reduced and CAM-
modi¢ed lipophilin C to be 8854.94 and 9025.74, respectively.
The mass di¡erence of 170.80 AMU indicated that component
C also contained three half-cystine residues. The measured
mass of the parent lipophilin heterodimer (16 424.01) corre-
sponded to the calculated mass (16 423.63) of a heterodimer
that contained one molecule of component A (7574.69 AMU)
linked to one molecule of component C (8854.94 AMU) by
three intramolecular disul¢de bonds. This calculation takes
into account that formation of three disul¢des will cause the
loss of 6 AMU.
3.6. Primary sequences of components A and C
The complete primary sequence of lipophilin A was deter-
mined by peptide sequencing and is shown in Fig. 5. Lipo-
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Fig. 5. Primary amino acid sequences of lipophilins A and C. The
singly underlined residues were obtained by directly sequencing
CAM-modi¢ed puri¢ed lipophilins A and C. Residues shown in
bold type were obtained by sequencing HPLC-puri¢ed, cyanogen
bromide fragments of carboxamidomethylated lipophilin compo-
nents A and C.
Fig. 6. Lipophilin homology. In the top panel, human lipophilin component A (LpnA) is aligned with rat prostatein components C1 (PrC1)
and C2 (PrC2). In the middle panel, human lipophilin component C (LpnC) is aligned with rat prostatein component C3 (PrC3) and human
mammaglobin (Mmg). In the bottom panel, lipophilin C is aligned with lacryglobin, a human tear peptide whose partial sequence was recently
reported [2]. Identical residues are connected by vertical lines (|) and similar residues are denoted by a +. The conserved cysteines are bolded.
Fig. 4. Separation of lipophilins A and C. Puri¢ed lipophilin dimer
was reduced with dithiothreitol and chromatographed on a small C-
18 column with a 1% min31 gradient of acetonitrile in 0.1% tri-
£uoroacetic acid. Elution was monitored at 230 nm (left panel) and
at 280 nm (right panel).
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philin A contained 69 residues and had a calculated pI of
9.47. The calculated mass of its reduced form, 7575.1, agreed
almost perfectly with the measured mass of the lipophilin A
we had puri¢ed from tears (7574.69), indicating that the tear
molecule was not glycosylated or otherwise post-translation-
ally modi¢ed.
Fig. 5 also shows the primary sequence of lipophilin C. The
¢rst 28 residues of this peptide had been established by se-
quencing the holopeptide, and we obtained 19 additional res-
idues by sequencing a cyanogen bromide fragment. The se-
quence was completed by cloning experiments, to be described
elsewhere. Component C was a 77-residue peptide with a cal-
culated pI of 4.94. The calculated mass of its reduced form
was 8854.07, which matched its measured mass (8854.94) al-
most perfectly. This measurement con¢rmed the results of our
ECL glycosylation studies, which also indicated that human
tear lipophilin C was not glycosylated.
3.7. Orientation in heterodimers
Having determined the primary sequences of the lipophilin
A and C monomers, we could decipher the double sequence
we had obtained for residues 1^25 in the lipophilin fragment
encountered at the outset of this work. It corresponded to the
N-terminal residues of both lipophilin components, A and C.
We concluded from this that lipophilin A and C monomers
associate head-to-head when they form AC heterodimers.
4. Discussion
This report describes the two peptides that comprise lipo-
philin AC, a heterodimeric molecule present in human tears.
Although lipophilin AC is relatively abundant, its existence in
tears has largely escaped prior detection. Only a single prior
report provides partial sequence data for any lipophilin com-
ponent [2], the peptide we have designated lipophilin C. These
investigators mapped human tear proteins by doing two-di-
mensional polyacrylamide gel electrophoresis, and ascertain-
ing the pI, approximate mass, amino acid composition and N-
terminal sequence of the separated proteins. Of the thirty tear
proteins mentioned in their report, only six (lysozyme, lipoca-
lin, and lactoferrin, cystatin S, cystatin N and zinc 2A-glyco-
protein) matched molecules described in the SWISS-PROT
database [2]. A molecule that they called ‘lacryglobin’ was
identical in 68/68 residues to component C of lipophilin.
These investigators also noted a second ‘lacryglobin spot’ on
their gels, and speculated that it might represent either C-
terminally processed lacryglobin (lipophilin C) or a highly
homologous but di¡erent gene product. Our data show that
lipophilin A (calculated pI 9.47) and lipophilin C (calculated
pI 4.94) di¡er markedly with respect to cationicity, making it
quite unlikely that their second lacryglobin spot corresponds
to lipophilin A.
The primary sequence data and heterodimeric structure of
human tear lipophilin shows remarkable similarity to that of
prostatein, a secreted molecule of the rat prostate gland (Fig.
6). Prostatein has also been called alpha protein [3], prostatic
steroid-binding protein [4] and EMBP or estramustine-binding
protein [5]. Prostatein/EMBP is a tetrameric molecule, com-
posed of three peptide components named C1, C2 and C3.
When we chromatographed human tears on a Sephadex G-
100 column, the elution pro¢le of lipophilin was consistent
with a tetrameric molecule composed of two AC heterodimers
(data not shown). Human lipophilin A is homologous to the
C1 and C2 components of rat prostatein, and human lipophil-
in C is homologous to rat prostatein component C3 (Fig. 6).
Whereas the C3 component of rat prostatein was reported
to be glycosylated [6], we found that human tear lipophilin
C is not. It was recently shown that the C3 component of
prostatein is also expressed in the rat lachrymal gland [7]
and that primary cultures of rat lachrymal gland cells respond
to androgens by secreting a prostatein-like molecule in vitro
[8].
The rat ventral prostate has been used extensively as a
model system to study the e¡ects of androgens. Prostatein/
EMBP constitutes 30^50% of the protein secreted by rat pros-
tate [7,9], and approximately 18^30% of total prostatic cyto-
solic protein [5]. As the synthesis of prostatein/EMBP is also
regulated by androgens [10], these features have made prosta-
tein a valuable experimental marker. Although there is immu-
nochemical evidence that prostatein-like molecules exist in
humans [11,12], the sequences of these molecules have not
been reported.
We have shown that the molecules, lipophilins A and C,
described in this report are homologous to two of the three
peptides that constitute rat prostatein/EMBP. In studies that
will be described elsewhere, we identi¢ed an additional human
peptide ^ lipophilin B ^ that is a homologue of human lip-
ophilin A and the C1 and C2 components of rat prostatein/
EMBP. Lipophilin component B was absent from tears, but
its mRNA was prominently expressed by human prostate and
other endocrine-responsive organs.
Lipophilin C is also homologous to mammaglobin, a re-
cently described human peptide frequently overexpressed in
breast cancer cells [13,14]. To date, mammaglobin has been
described only at the nucleotide level, and it remains to be
learned if it forms prostatein-like heterodimers or higher order
molecular assemblies with lipophilins A and B.
Several immunochemical studies have indicated that the
tumor cell expression of prostatein/EMBP can provide useful
prognostic information and perhaps predict responsiveness to
estramustine (Estracyt) treatment in patients with prostate
cancer [15^18] and other malignancies [19,20]. The precise
structural characterization of these human lipophilins will fa-
cilitate studies to examine their e¡ects on the responses of
normal and malignant cells to steroids. The nucleotide and
peptide sequences will also permit the design of more precise
probes to examine their tissue expression in health and dis-
ease.
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